August 15, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Seres Therapeutics Inc (NASDAQ:MCRB) shares over potential securities laws violations by Seres Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Seres Therapeutics Inc (NASDAQ:MCRB) concerning whether a series of statements by Seres Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 29, 2016, Seres Therapeutics Inc disclosed that its Phase 2 clinical study for ECOSPOR did not meet its primary endpoint of reducing the relative risk of Clostridium difficle infection recurrence. Shares of Seres Therapeutics Inc (NASDAQ:MCRB) declined on July 29, 2016 to as low as $8.05 per share.

According to the investigation just a couple days prior to this announcement, the Companys President, CEO and Chairman of the Board sold 20,000 shares of Seres at $35 per share, and another Company insider sold 38,064 shares at $35.12 per share.